|Description||CPPHA is a selective positive allosteric modulator of mGluR5 receptor. It is thought to act at a novel allosteric site and potentiates mGlu5 responses by a mechanism distinct from that of VU 29.|
Very selective nanomolar potent antagonist for group II mGlu receptors. Also a relatively potent antagonist for group III mGlu receptors at high nanomolar to lo...
Methoxy-PEPy is a potent and highly selective mGlu5 receptor antagonist.
ADX-47273 is a drug used in scientific research which acts as a positive allosteric modulator selective for the metabotropic glutamate receptor subtype mGluR5.
TCN238 is an orally available, brain penetrant and positive allosteric mGlu4 receptor modulator (EC50= 1 μM) with 30-fold selectivity over mGluR5 using human re...
JNJ-40411813 is a novel positive allosteric modulator of the metabotropic Glutamate 2 receptor (mGlu2R) with EC50 of 147 nM.
Potent and selective antagonist for metabotropic glutamate receptor subtype 5 (mGluR5); Systemically active in vivo.
Raseglurant is a negative allosteric modulator of the mGlu5 receptor and derivative of MPEP. It can be used for the treatment of migraine, gastroesophageal refl...
RG7090 is a negative modulator of metabotropic glutamate receptor subtype 5 (mGluR5; GRM5).
L-Glutamine is one of the 20 amino acids encoded by the standard genetic code.
BMT-145027 is a potent mGluR5 PAM without inherent agonist activity with an EC50 of 47 nM. BMT-145027 is a non-MPEP site PAM to demonstrate in vivo efficacy.
FITM is a potent mGlu1 inhibitor (Ki = 2.5 nM) with great selectivity that does not disrupt mGlu5.
CTEP is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor (IC50=2.2 nM), showing >1000-fold selectivity over other mGlu receptor...
(1R,2S)-VU0155041 is a partial mGluR4-positive allosteric modulator (EC50= 2.35 μM) that dependently attenuated hyperalgesia in neuropathic pain model rats.
Fenobam is a potent, selective, noncompetitive glutamate mGluR5 receptor antagonist. It displays inverse agonist properties. It blocks mGluR5 constitutive activ...
Dipraglurant is a mGlu5 receptor negative allosteric modulator. It is currently in phase II for the treatment of dyskinesia in Parkinson's disease.
BAY 36-7620 elective mGlu1 receptor non-competitive antagonist (IC50 = 0.16 μM) with inverse agonist activity.
LY2979165 is a mGlu2 agonist, which is a novel potent agent that is used as anti-depressants.
VU-0483605, an isoindol derivative, has been found to be a mGluR1 positive allosteric modulator and probably be effective against schizophrenia. EC50: 356 and 3...